Travis Evans
Family · Blackfoot, IDNPI 1861742702
Payments from drug & device makers
Across 61 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$300
- Novartis$203
- Lilly USA, LLC$189
- Agios Pharmaceuticals, Inc.$125
- Regeneron Healthcare Solutions, Inc.$121
- Genentech USA, Inc.$96
- plus $393 from 14 others
What the payments were for
- Food & beverage$1,427100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $300 |
| Novartis | 9 | $203 |
| Lilly USA, LLC | 13 | $189 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $121 |
| Genentech USA, Inc. | 5 | $96 |
| Daiichi Sankyo Inc. | 1 | $59 |
| Amgen | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| AstraZeneca | 2 | $32 |
| Merck | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $27 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $26 |
| Edwards Lifesciences | 1 | $25 |
| GE HealthCare | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,427 in reported general payments places this provider in the 75th percentile of 809 family providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $43,012 |
| Varenicline Tartrate | 18 | $3,747 |
| Insulin Aspart FlexpenInsulin Aspart | 12 | $3,251 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,340 |
| Levothyroxine Sodium | 184 | $1,278 |
| Gabapentin | 77 | $1,226 |
| Rosuvastatin Calcium | 142 | $1,182 |
| Colestipol Hcl | 15 | $986 |
| Celecoxib | 13 | $910 |
| Carbamazepine ErCarbamazepine | 12 | $891 |
| Omeprazole | 82 | $814 |
| Potassium Chloride | 35 | $665 |
| Duloxetine Hcl | 25 | $620 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $594 |
| Olmesartan Medoxomil | 36 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $189 | $43,01242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 809 family providers in Idaho.
Other family in Blackfoot
- Jessica DanceBlackfoot$4K
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.